Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3
MONDO:0956997An IDH-mutant, and 1p/19q-codeleted oligodendroglioma that is characterized as grade 3 tumors associated with a more rapid growth. Grade 3 tumors appear to have abnormalities on chromosomes 9 or 10, along with unusual amounts of growth factors and proteins, which are thought to contribute to the more rapid growth of these gliomas.
2832 clinical trials for this condition and its sub-types, 3 tagged with Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Oral Brain-Penetrating drug tested against aggressive IDH1-Mutant gliomas
Disease control Not yet recruitingResearchers are testing an oral drug called safusidenib in adults newly diagnosed with IDH1-mutant grade 3 oligodendroglioma or astrocytoma, two types of brain tumor. Safusidenib is designed to cross into the brain and block the mutated IDH1 enzyme that drives these tumors. All 2…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
New hope for deadly brain cancer? early trial launches
Disease control Not yet recruitingThis early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the…
Phase 1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC